Position Statement Identification and Management of Cardiometabolic Risk in Canada: A Position Paper by the Cardiometabolic Risk Working Group (Executive Summary)

With the objectives of clarifying the concepts related to “cardiometabolic risk,” “metabolic syndrome” and “risk stratification” and presenting practical strategies to identify and reduce cardiovascular risk in multiethnic patient populations, the Cardiometabolic Working Group presents an executive summary of a detailed analysis and position paper that offers a comprehensive and consolidated approach to the identification and management of cardiometabolic risk. The above concepts overlap and relate to the atherogenic process and development of type 2 diabetes. However, there is confusion about what these terms mean and how they can best be used to improve our understanding of cardiovascular disease treatment and prevention. The concepts related to cardiometabolic risk, pathophysiology, and strategies for identification and management (including health behaviours, pharmacotherapy, and surgery) in the multiethnic Canadian population are presented. “Global cardiometabolic risk” is proposed as an umbrella term for a comprehensive list of existing and emerging factors that predict cardiovascular disease and/or type 2 diabetes. Health behaviour interventions (weight loss, physical activity, diet, smoking cessation) in people identified at high cardiometabolic risk are of critical importance given the emerging crisis of obesity and the consequent epidemic of type 2 diabetes. Vascular protective measures (health behaviours for all patients and pharmacotherapy in appropriate patients) are essential to reduce cardiometabolic risk, and there is growing consensus that a multidisciplinary approach is needed to adequately address cardiometabolic risk factors. Health care professionals must also consider ethnicity-related risk factors in order to appropriately evaluate all individuals in their diverse patient

[1]  R. Ross,et al.  Cardiometabolic Risk in Canada: a Detailed Analysis and Position Paper by the Cardiometabolic Risk Working Group Introduction to the Concepts of Cardiometabolic Risk, Metabolic Syndrome, and Risk Stratification: Finding the Forest among the Trees E2 , 2022 .

[2]  Arya M. Sharma,et al.  Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. , 2010, The New England journal of medicine.

[3]  Salim Yusuf,et al.  Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. , 2010, Journal of the American College of Cardiology.

[4]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[5]  M. Laakso,et al.  Effect of nateglinide on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[6]  E. Ingelsson,et al.  Impact of Body Mass Index and the Metabolic Syndrome on the Risk of Cardiovascular Disease and Death in Middle-Aged Men , 2010, Circulation.

[7]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[8]  Robert Dufour,et al.  Canadian Cardiovascular Society / Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations , 2009 .

[9]  L. Fleisher,et al.  Cardiovascular Evaluation and Management of Severely Obese Patients Undergoing Surgery: A Science Advisory From the American Heart Association , 2009, Circulation.

[10]  S. Verma,et al.  Statin Effects on LDL and HDL Cholesterol in South Asian and White Populations , 2009, Journal of clinical pharmacology.

[11]  G. Bakris,et al.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.

[12]  C. Apovian,et al.  American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery Medical Guidelines for Clinical Practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. , 2008, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[13]  P. Poirier.  Healthy lifestyle: even if you are doing everything right, extra weight carries an excess risk of acute coronary events. , 2008, Circulation.

[14]  P. Macfarlane,et al.  Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies , 2008, The Lancet.

[15]  Philippe Pibarot,et al.  Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[16]  S. Yusuf,et al.  Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose , 2008, Diabetes Care.

[17]  J. Després,et al.  The concept of cardiometabolic risk: Bridging the fields of diabetology and cardiology , 2008, Annals of medicine.

[18]  P. Nilsson.  Cardiovascular risk in the metabolic syndrome: Fact or fiction? , 2007, Current cardiology reports.

[19]  Claude Bouchard,et al.  Effects of bariatric surgery on mortality in Swedish obese subjects. , 2007, The New England journal of medicine.

[20]  Steven C Hunt,et al.  Long-term mortality after gastric bypass surgery. , 2007, The New England journal of medicine.

[21]  R. Devereux,et al.  Prognostic Impact of Metabolic Syndrome by Different Definitions in a Population With High Prevalence of Obesity and Diabetes , 2007, Diabetes Care.

[22]  C. Barbagallo,et al.  The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population. , 2007, Atherosclerosis.

[23]  M. Simoons,et al.  Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial , 2007, Heart.

[24]  B. Hedblad,et al.  The metabolic syndrome and incidence of cardiovascular disease in non‐diabetic subjects—a population‐based study comparing three different definitions , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[25]  J. Douketis,et al.  2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary] , 2007, Canadian Medical Association Journal.

[26]  G. Bakris.  Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome , 2007, Diabetes Care.

[27]  J. Liao.  Safety and efficacy of statins in Asians. , 2007, The American journal of cardiology.

[28]  Victor M Montori,et al.  Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. , 2007, Journal of the American College of Cardiology.

[29]  Jiang He,et al.  Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. , 2006, The American journal of medicine.

[30]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[31]  S. Yusuf,et al.  Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials , 2006, The Lancet.

[32]  N. Sattar.  The metabolic syndrome: should current criteria influence clinical practice? , 2006, Current Opinion in Lipidology.

[33]  J. Shaw,et al.  Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[34]  B. Zinman,et al.  Characteristics and prevalence of the metabolic syndrome among three ethnic groups in Canada , 2006, International Journal of Obesity.

[35]  Gianni Tognoni,et al.  Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials , 2006, JAMA.

[36]  D. Herrington,et al.  Diabetes, the Metabolic Syndrome, and Angiographic Progression of Coronary Arterial Disease in Postmenopausal Women , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[37]  M. Caulfield,et al.  Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) , 2005, The Lancet.

[38]  J. Després,et al.  Impact of Waist Circumference on the Relationship Between Blood Pressure and Insulin: The Quebec Health Survey , 2005, Hypertension.

[39]  Steve N Caritis,et al.  Elective single-embryo transfer versus double-embryo transfer in in vitro fertilization , 2004, The New England journal of medicine.

[40]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[41]  S. Grundy,et al.  Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[42]  S. Grundy,et al.  Clinical Management of Metabolic Syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management , 2004, Circulation.

[43]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[44]  C. Nishida,et al.  Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies , 2004, The Lancet.

[45]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[46]  S. Teutsch,et al.  NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. , 2003, Diabetes.

[47]  A. Dougherty,et al.  Cardiovascular consequences of obesity. , 2003 .

[48]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[49]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[50]  S. Yusuf,et al.  Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE) , 2000, The Lancet.

[51]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.

[52]  Lawrence A Leiter,et al.  Canadian Diabetes Association Clinical Practice Guidelines Expert Committee , 2013 .

[53]  J. Dungan.  Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study , 2011 .

[54]  S. Mudaliar,et al.  Actos Now for the prevention of diabetes (ACT NOW) study , 2009, BMC endocrine disorders.

[55]  J. Després,et al.  Visceral obesity and the heart. , 2008, The international journal of biochemistry & cell biology.

[56]  L. Sjöström,et al.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.

[57]  C. Lawton.  Highlights of the 2003 Clinical Practice Guidelines for the prevention and management of diabetes in Canada. , 2004, CANNT journal = Journal ACITN.

[58]  S. Teutsch,et al.  THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES III); NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP). NCEP-DEFI NED METABOLIC SYNDROME, DIABETES, AND PREVALENCE OF CORONARY HEART DISEASE AMONG NHANES III PARTICIPANTS AGE 50 YEARS AND OLDER , 2003 .

[59]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002, The New England journal of medicine.